Citicoline

Full profile

Evidence, honestly graded

Downgraded from B to C on 2026-09-14, on three grounds. First, the trials behind the branded form's attention claim are all tied to Cognizin's manufacturer, Kyowa Hakko Bio, through funding or co-authorship: McGlade 2012 (women, 28 days), McGlade 2019 (adolescent boys, 28 days) and Nakazaki 2021 (older adults, 12 weeks; Kyowa funded it and took part in its design, though the paper reports Kyowa was not involved in the intervention, data collection or statistical analysis). That is sponsor dependence rather than independent confirmation. Second, the healthy-adult evidence from outside those trials points to a narrower effect than the marketing does: an academically funded crossover trial (Knott 2015, n=24, single 500 or 1,000 mg doses) improved cognition only in people who started as low performers, found nothing in medium performers, and reduced performance in high performers. An older trial in adults aged 50–85 (Spiers 1996) improved memory mainly in participants whose recall was inefficient to begin with (a subgroup identified after the initial analysis), and while it carried NIH grant support, the journal later published a correction supplying a financial-disclosure statement the paper had omitted, setting out authors' financial ties to Interneuron and Ferrer, companies with commercial interests in citicoline, so it is not independent of commercial interest in the compound either. Third, independent review and large trials have gone against the compound: EFSA's 2024 health-claim opinion found no cause-and-effect relationship between citicoline and memory, and two large citicoline RCTs were both null: ICTUS in acute stroke (n=2,298), funded by the citicoline manufacturer Ferrer, and COBRIT in traumatic brain injury (n=1,213), sponsored by the US National Institutes of Health. Those are clinical populations rather than healthy adults, but they are large, well-powered tests of the compound. Two completed healthy-adult trials, one testing 250 mg and one in adults aged 18–35, had no posted results when we checked on 2026-09-14. A well-conducted independent trial showing a benefit at label doses in healthy adults would move this back toward B. Health Canada's sustained-attention monograph claim is unaffected; a permitted claim is not the same as a strong evidence grade.

See the full grading rubric (study type, replication, population match, and dose adequacy) in The Evidence Standard.

Side effects

• Generally well tolerated
• Occasional headache or GI discomfort reported

Who should avoid it or check first

• Pregnant or breastfeeding without clinician guidance

Interactions

• Discuss with a clinician if taking medications affecting acetylcholine pathways

Stacks well with

• L-Theanine
• Bacopa Monnieri

Use caution stacking with

• Redundant to combine multiple high-dose choline sources without rationale

What to look for on a label

• Check the elemental citicoline dose per serving.
• Branded forms should be named and dosed transparently.

References

• McGlade E, Locatelli A, Hardy J, et al. (2012). Food and Nutrition Sciences, 3(6):769–773Randomized, double-blind, placebo-controlled, n=60 women aged 40–60, 28 daysStudied dose: 250 mg and 500 mg dailyFewer commission errors on a sustained-attention test versus placebo at both doses.
• Nakazaki E, Mah E, Sanoshy K, et al. (2021). The Journal of Nutrition, 151(8):2153–2160Randomized, double-blind, placebo-controlled, n=100 aged 50–85, 12 weeksStudied dose: 500 mg dailyImproved episodic memory measures versus placebo in a healthy older sample.
• McGlade E, Agoston AM, DiMuzio J, et al. (2019). Journal of Attention Disorders, 23(2):121–134Randomized, double-blind, placebo-controlled, n=75 healthy adolescent males, 28 daysStudied dose: 250 mg or 500 mg dailyImproved attention and psychomotor speed versus placebo; higher weight-adjusted doses were associated with better attention accuracy.
• Knott V, de la Salle S, Choueiry J, et al. (2015). Pharmacology, Biochemistry and BehaviorRandomized, double-blind, placebo-controlled crossover, n=24 healthy male volunteers, single dosesStudied dose: 500 mg or 1000 mg (single doses)Improved processing speed, working memory, verbal learning and memory, and executive function in low baseline performers; no effect in medium performers; reduced performance in high performers.
• Spiers PA, Myers D, Hochanadel GS, et al. (1996). Archives of Neurology, 53(5):441–448Randomized, double-blind, placebo-controlled, n=95 adults aged 50–85 over 3 months, with a 32-person crossover phaseStudied dose: 1 g/day (2 g/day in the crossover phase)Improved delayed recall mainly in participants whose memory was inefficient at baseline; the higher dose improved logical memory in the crossover phase.
• EFSA NDA Panel (2024): citicoline and memory function. Scientific opinion on a proposed EU health claim: a cause-and-effect relationship between citicoline and memory in middle-aged and older adults with subjective memory complaints was not established. One positive trial at 500 mg/day was not supported by a null trial at 1 g/day or by dementia data. PMID 38966137; doi:10.2903/j.efsa.2024.8861. The main independent basis for the C grade.
• Dávalos 2012, Lancet: ICTUS trial. International RCT of citicoline in 2,298 people with moderate-to-severe acute ischaemic stroke; neutral result on recovery at 90 days. Funded by Ferrer Grupo, a citicoline manufacturer. PMID 22691567. Clinical population, cited as a large test of the compound, not as healthy-adult evidence.
• Zafonte 2012, JAMA: COBRIT trial. Phase 3 RCT of citicoline in 1,213 people with traumatic brain injury; no improvement in functional or cognitive status at 90 days. Sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NIH). PMID 23168823. Clinical population.
• Completed trials without posted results (re-checked 2026-09-17). ClinicalTrials.gov NCT05000190 (PepsiCo; 250 mg/day for 28 days in 104 healthy adults; completed July 2022) and NCT06906848 (Kirin Holdings; Cognizin for 12 weeks in 90 adults aged 18–35; completed June 2025). Still no posted results when we re-checked on 2026-09-17; the PepsiCo record has not been updated since November 2022 and the Kirin record since July 2025. Unreported is not the same as negative; these are the results most likely to move this grade.

Entries above without a linked identifier are either editorial summaries of a wider body of literature or references to a named authority (a regulator or government monograph) cited by name rather than by a single paper.

Grades and studied doses are our conservative reading of the human research, shown for education. They are not product claims, and a studied dose is not a recommended dose.

Revision history

Every change to this ingredient's evidence status, dated and explained. The full cross-library log lives at Evidence Updates.

• 2026-09-17Citation review

  Re-checked both trials this grade is waiting on. NCT05000190 (PepsiCo, 250 mg) and NCT06906848 (Kirin) still had no posted results on 2026-09-17, and neither registry record has been updated since 2022 and 2025 respectively. No new healthy-adult citicoline trial has appeared. C holds, still under monitoring.

• 2026-09-17Citation review

  Corrected how three trials' sponsorship is described. Spiers 1996 was counted as independent healthy-adult evidence; Archives of Neurology published a correction supplying a financial-disclosure statement the paper had omitted, setting out authors' financial ties to Interneuron and Ferrer, companies with commercial interests in citicoline. ICTUS, one of the two large null trials, was described as independent; it was funded by Ferrer, a citicoline manufacturer. Nakazaki 2021 was described as manufacturer-run; Kyowa funded it and took part in its design, but the paper reports Kyowa was not involved in the intervention, data collection or statistical analysis. Knott 2015 remains the independent healthy-adult trial. The grade is unchanged at C.

• 2026-09-14Grade changeGrade B → Grade C

  Downgraded from B to C. The trials behind the branded form's attention claim are all funded by or co-authored with its manufacturer; the healthy-adult work from outside them is small and concentrated in low baseline performers (Knott 2015, and Spiers 1996, whose authors' financial ties to citicoline companies were disclosed in a later correction); EFSA's 2024 review found no cause-and-effect relationship for memory; and two large RCTs were null (ICTUS in stroke, funded by the citicoline manufacturer Ferrer; COBRIT in brain injury, sponsored by the NIH). Two completed healthy-adult trials had no posted results when we checked.

• 2026-07-04New profile

  Initial profile published at Grade B: several human trials report attention and memory measures, though both principal supporting trials are tied to the branded-form manufacturer — a sponsor-dependence caveat behind the grade.

See how Citicoline compares on grade, dose, and goal in the Evidence Explorer.